OOIR: Observatory of International Research

Papers

(The median citation count of Drug Resistance Updates is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)

Article	Citations
lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2	203
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer	194
Acquired non-thermal plasma resistance mediates a shift towards aerobic glycolysis and ferroptotic cell death in melanoma	192
Editorial Board	183
Editorial Board	140
Editorial Board	137
Editorial Board	128
Modulating undruggable targets to overcome cancer therapy resistance	120
LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein	105
Circulating tumor cells with increasing aneuploidy predict inferior prognosis and therapeutic resistance in small cell lung cancer	96
Intersecting pathways: The role of hybrid E/M cells and circulating tumor cells in cancer metastasis and drug resistance	82
CircPDIA3/miR-449a/XBP1 feedback loop curbs pyroptosis by inhibiting palmitoylation of the GSDME-C domain to induce chemoresistance of colorectal cancer	79
Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins	74
Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases	74
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells	69
CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer	68
CCT251545 enhances drug delivery and potentiates chemotherapy in multidrug-resistant cancers by Rac1-mediated macropinocytosis	67
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming	67
The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity	66
GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells	65
Silver-dendrimer nanocomposite as emerging therapeutics in anti-bacteria and beyond	59
Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma	56
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma	55
Upregulation of CoQ shifts ferroptosis dependence from GPX4 to FSP1 in acquired radioresistance	54
Prophylactic use of antibiotics – A strategy with unforeseen risks?	53

Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea	53
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor	52
Widespread loss-of-function mutations implicating preexisting resistance to new or repurposed anti-tuberculosis drugs	52
Surface chemistry engineered selenium nanoparticles as bactericidal and immuno-modulating dual-functional agents for combating methicillin-resistant Staphylococcus aureus Infection	50
A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis	47
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment	44
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment	44
Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance	44
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance	43
Molecular Modeling Strategies of Cancer Multidrug Resistance	43
Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics	40
MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma	37
Antibiotic failure: Beyond antimicrobial resistance	37
Novel nanomedicines to overcome cancer multidrug resistance	35
CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance	35
CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification	35
Hypoxia as a driver of resistance to immunotherapy	35
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance	35
Paclitaxel resistance related to nuclear envelope structural sturdiness	35
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy	34
Exploring Treatment-Driven Subclonal Evolution of Prognostic Triple Biomarkers: Dual Gene Fusions and Chimeric RNA Variants in Novel Subtypes of Acute Myeloid Leukemia Patients with KMT2A Rearrangemen	34
Hallmarks of anticancer and antimicrobial activities of corroles	33
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	33
Editorial Board	29
Anticancer drug resistance: An update and perspective	29
Multi-omics dissection of stage-specific artemisinin tolerance mechanisms in Kelch13-mutant Plasmodium falciparum	28
Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression	27
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer	26
Editorial Board	26
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms	26
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance	26
Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer	26
Editorial Board	26
New emerging SARS-CoV-2 variants and antiviral agents	25
Overexpression of blaGES-1 due to a strong promoter in the class 1 integron contributes to decreased ceftazidime-avibactam susceptibility in carbapenem-resistant Pseudomonas aeruginosa ST235	25
Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance	25
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	23
KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner	22
Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer	21
AI-driven visualization tool for analyzing data and predicting drug-resistant outbreaks	21
Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae	20
Cisplatin-activated ERβ/DCAF8 positive feedback loop induces chemoresistance in non-small cell lung cancer via PTEN/Akt axis	20
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	19
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy	19
Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells	19
Acetate utilization promotes hormone therapy resistance in prostate cancer through neuroendocrine differentiation	18
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma	18
Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer	18
Understanding ER homeostasis and the UPR to enhance treatment efficacy of acute myeloid leukemia	17
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance	17

Unraveling the secrets: Evolution of resistance mediated by membrane proteins	17
Corrigendum to “Molecular basis of bacterial disinfectant resistance” [Drug Resist. Updates 48 (2020) 100672]	17
crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer	17
NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1	16
CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer	15
A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer	15
Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency	15
Cross-resistance and drug sequence in prostate cancer	15
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies	15
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges	14
Editorial Board	14
Genetic alterations shaping tumor response to anti-EGFR therapies	14
The role of endolysosomal trafficking in anticancer drug resistance	13
Characterization of NMCR-3, NMCR-4 and NMCR-5, three novel non-mobile colistin resistance determinants: Implications for MCR-3, MCR-7, and MCR-5 progenitors, respectively	12
Identification of TMexCD-TOprJ-producing carbapenem-resistant Gram-negative bacteria from hospital sewage	12
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine	12
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer	12
TRAIL-driven targeting and reversing cervical cancer radioresistance by seleno-nanotherapeutics through regulating cell metabolism	12
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA	12
Evolution of RND efflux pumps in the development of a successful pathogen	12
Editorial Board	11
Vaccine effects on COVID-19 infection with bivalent boosting by age group	11
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance	11
Editorial Board	11
CPSF6-mediated XBP1 3’UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma	10
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP	10
Editorial Board	10
Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness	10
MYC expression and fatty acid oxidation in EGFR-TKI acquired resistance	10
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China	9
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability	9
Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?	9
BCL7A inhibits the progression and drug-resistance in acute myeloid leukemia	9
Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration	9
Antimicrobial peptides for combating drug-resistant bacterial infections	8
Editorial: ABC transporters and drug resistance	8
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae	8
Breaking the barrier: Epigenetic strategies to combat platinum resistance in colorectal cancer	8
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition	8
Global phylogeography and antibiotic resistance characteristics of Morganella: An epidemiological, spatial, comparative genomic study	7
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerability	7
Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling	7
Mechanism of staphylococcal resistance to clinically relevant antibiotics	7
Targeted nanomedicine modalities for prostate cancer treatment	6
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement	6
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs	6
In vitro biomimetic models for glioblastoma-a promising tool for drug response studies	6
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers	6
Single-cell transcriptional profiling uncovers the association between EOMES+CD8+ T cells and acquired EGFR-TKI resistance	6
E3 ubiquitin ligase DTX2 fosters ferroptosis resistance via suppressing NCOA4-mediated ferritinophagy in non-small cell lung cancer	6
Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2	6
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation	6
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer	5
Tumor-acquired somatic mutation affects conformation to abolish ABCG2-mediated drug resistance	5
Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics	5
NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide	5
Intercellular adhesion molecule-1 suppresses TMZ chemosensitivity in acquired TMZ-resistant gliomas by increasing assembly of ABCB1 on the membrane	5
Editorial Board	5
Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies	5
Second-site suppressor mutations reveal connection between the drug-binding pocket and nucleotide-binding domain 1 of human P-glycoprotein (ABCB1)	5
Editorial Board	4
Editorial Board	4
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs	4
Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat	4
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome	4
Editorial Board	4
Editorial Board	4
The prospects of tumor chemosensitivity testing at the single-cell level	4
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond	4
A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+CD24- enriched breast cancer stem-like cells	4
AI in infectious diseases: The role of datasets	4
Editorial Board	4
Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy	4
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC	4
Targeting anoikis resistance as a strategy for cancer therapy	4